Ahmet Dirican, Professor of Medical Oncology at Medicana International İzmir Hospital, shared a post on X:
“Could a ketogenic diet improve outcomes in pancreatic cancer?
A randomized phase II screening trial evaluated a medically supervised ketogenic diet added to chemotherapy in metastatic PDAC. Encouraging – but not practice-changing.
Results showed an interesting signal:
- PFS: 8.5 vs 6.2 months (HR 0.53; p = 0.096, one-sided).
- OS: 13.7 vs 10.2 months (HR 0.58; p = 0.209).
One important concern:
Pancreatic cancer is strongly associated with cachexia and muscle loss.
If caloric intake is insufficient, ketogenic diets could potentially worsen sarcopenia. Importantly, body composition monitoring was limited in this study, making it difficult to understand the real metabolic impact.
Promising concept – but better-designed trials with careful nutritional and muscle mass monitoring are needed.”
Title: A randomized phase II trial of gemcitabine, nab‐paclitaxel, cisplatin with or without a medically supervised ketogenic diet for patients with metastatic pancreatic cancer
Authors: Gayle S. Jameson, Denise J. Roe, Erkut Borazanci, Diana L. Hanna, Caroline G. P. Roberts, Meredith S. Pelster, Richard C. Frank, Angela T. Alistar, Alan M. Miller, J. Erin Wiedmeier-Nutor, Sandra D. Algaze, Alison R. Zoller, Sarah J. Hallberg, Betsy C. Wertheim, Keehoon Lee, Derek Cridebring, Joshua D. Rabinowitz, Stephen Gately, Jennifer Keppler, Sunil Sharma, Daniel D. Von Hoff, Drew W. Rasco.
Read The Full Article
Other articles about Pancreatic Cancer on OncoDaily.
